



RON DESANTIS  
GOVERNOR

SIMONE MARSTILLER  
SECRETARY

July 23, 2021

## Statewide Medicaid Managed Care (SMMC) Policy Transmittal: 2021-25

Applicable to the **2018-2023 SMMC contract benefits** for:

- Managed Medical Assistance (MMA) and MMA Specialty
- Long-Term Care (LTC)
- Dental

### Re: Coverage of Medication Assisted Treatment (MAT) Drugs

The managed care plan's prior authorization criteria and protocols for prescribed drugs must not be more restrictive than those posted on the Agency website and used by the Agency, as authorized by federal and State laws, rules, or regulations, and the federal CMS waivers applicable to this contract. (Attachment II, Exhibit II-A, Section VI.G.4.b.) The purpose of this policy transmittal is to notify the managed care plan of system edits that must be implemented for MAT drugs.

While MAT drugs are already covered by Florida Medicaid, effective September 15, 2021, the managed care plan must ensure the following edits are implemented to facilitate access and remove barriers (i.e., paper prior authorization) in obtaining MAT drugs.

- Automatic approval that allows MAT therapy if a Florida Medicaid recipient has a diagnosis of opioid use disorder in the Florida Medicaid pharmacy database.
- Pharmacy level override if the diagnosis of opioid use disorder is provided on the prescription.
- Call center capability of entering approval override via phone request when a prescriber calls and confirms their patient has an opioid use disorder diagnosis.

The Florida Medicaid fee-for-service delivery system has already implemented the above edits for recipients who are sixteen (16) years of age and older with an opioid use disorder diagnosis. This MAT edit allows recipients to receive the oral preferred buprenorphine containing medications:

- Buprenorphine sublingual tablets
- Buprenorphine/naloxone tablets
- Suboxone film (buprenorphine/naloxone)
- Zubsolv sublingual tablets (buprenorphine/naloxone)



Statewide Medicaid Managed Care (SMMC) Policy Transmittal 2021-25  
Re: Coverage of Medication Assisted Treatment (MAT) Drugs  
July 23, 2021  
Page 2 of 2

If you have questions or concerns, please contact your Agency contract manager.

Sincerely,

A handwritten signature in blue ink that reads "Tom Wallace". The signature is written in a cursive, flowing style.

Tom Wallace  
Deputy Secretary for Medicaid

TW/sar